- Home
- TMQ vs JANX Comparison
TMQ vs JANX Comparison
Compare TMQ & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMQ | JANX |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 700.5M | 790.3M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TMQ | JANX |
|---|---|---|
| Price | $3.87 | $15.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $53.60 |
| AVG Volume (30 Days) | ★ 2.8M | 949.6K |
| Earning Date | 04-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.17 | $12.12 |
| 52 Week High | $11.29 | $35.34 |
Technical Indicators
Market Signals| Indicator | TMQ | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 61.72 |
| Support Level | $3.79 | $13.10 |
| Resistance Level | $4.55 | $15.49 |
| Average True Range (ATR) | 0.24 | 0.56 |
| MACD | 0.10 | 0.11 |
| Stochastic Oscillator | 60.27 | 83.61 |
Price Performance
Historical ComparisonAbout TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.